EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients

Publisher： Karger

E-ISSN： 2296-5262|28|12|623-627

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.12, 2005-12, pp. : 623-627

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 435-443

Karger

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite